A Modified Blumgart Pancreaticojejunostomy in Laparoscopic Pancreaticoduodenectomy: A Retrospective Study
World Journal of Surgery · 2026-11-08
DOI: 10.1002/wjs.70659 ↗Abstract
ABSTRACT Background Laparoscopic pancreaticoduodenectomy (LPD) is increasingly performed, but clinically relevant postoperative pancreatic fistula (CR‐POPF) remains a major complication. This study evaluated a modified Blumgart pancreaticojejunostomy (PJ) technique in LPD. Methods This retrospective study included 217 consecutive patients who underwent LPD between January 2021 and December 2025. 102 in the modified Blumgart group and 115 in the conventional Blumgart group. 1:1 propensity score matching (PSM) was performed using 12 covariates based on the Fistula Risk Score model. The primary outcome was CR‐POPF. Univariate and multivariate logistic regression identified independent risk factors, and exploratory subgroup analyses were conducted. Results After PSM, 78 patients remained in each group. In the entire cohort, the modified group had a significantly lower CR‐POPF rate (6.9% vs. 17.4%, p = 0.019) and fewer abdominal infections (5.9% vs. 15.7%, p = 0.022). After PSM, CR‐POPF remained lower in the modified group (7.7% vs. 17.9%, p = 0.055), and abdominal infection remained significantly reduced (6.4% vs. 16.7%, p = 0.045). Multivariate analysis identified PDAC pathology (OR = 0.233, p = 0.022) and modified anastomosis (OR = 0.383, p = 0.041) as independent protective factors in the entire cohort. Subgroup analysis revealed that the protective effect was shown in patients with a main pancreatic duct > 3 mm (OR = 0.176, p = 0.008; PSM cohort: OR = 0.169, p = 0.027; p for interaction = 0.070 and 0.111, respectively). Conclusions The modified Blumgart PJ is safe and effective in LPD, reducing CR‐POPF and abdominal infection. Its protective effect is shown in patients with a main pancreatic duct > 3 mm.
EUVIMED